Drugs / Enarodustat
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02805244 | Jun → Sep 2016 | anemia due to chronic disorder | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02581124 | Oct 2015 → Apr 2016 | anemia due to chronic disorder | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01978587 | Oct → Dec 2013 | anemia due to chronic disorder | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01971164 | May 2013 → May 2014 | anemia due to chronic disorder | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06737081 | Sep 2024 → Dec 2025 overdue | anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07522996 | Jun 2026 → Dec 2028 | aplastic anemia | Peking Union Medical College Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT07548671 | Apr 2026 → Dec 2028 expected | aplastic anemia | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04027517 | Jan 2019 → Feb 2021 | anemia due to chronic disorder | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07079579 | Aug 2025 → Jun 2027 expected | aregenerative anemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06725810 | Mar 2025 → Jan 2029 expected | anemia due to chronic disorder | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Enarodustat | “Enarodustat (SAL-0951) Tablets” NCT06737081 ↗ |
| Known as | JTZ-951 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02581124 ↗ |
| Known as | SAL-0951 | “Enarodustat (SAL-0951) Tablets” NCT06737081 ↗ |
| Action | Inhibit | “Egl nine homolog 1 inhibitor” CHEMBL4297619 ↗ |
| Modality | Small molecule | — CHEMBL4297619 ↗ |
| Route | Oral | “Tablets, 1 dose per day for 15 days” NCT01971164 ↗ |
| Target | EGLN1 | “Egl nine homolog 1 inhibitor” CHEMBL4297619 ↗ |